- Home
- DSP vs ITOS Comparison
DSP vs ITOS Comparison
Compare DSP & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- ITOS
- Stock Information
- Founded
- DSP 1999
- ITOS 2011
- Country
- DSP United States
- ITOS United States
- Employees
- DSP N/A
- ITOS N/A
- Industry
- DSP EDP Services
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DSP Technology
- ITOS Health Care
- Exchange
- DSP Nasdaq
- ITOS Nasdaq
- Market Cap
- DSP 220.3M
- ITOS 381.2M
- IPO Year
- DSP 2021
- ITOS 2020
- Fundamental
- Price
- DSP $13.06
- ITOS $10.26
- Analyst Decision
- DSP Strong Buy
- ITOS Hold
- Analyst Count
- DSP 8
- ITOS 6
- Target Price
- DSP $21.75
- ITOS $10.60
- AVG Volume (30 Days)
- DSP 209.9K
- ITOS 793.1K
- Earning Date
- DSP 08-11-2025
- ITOS 08-07-2025
- Dividend Yield
- DSP N/A
- ITOS N/A
- EPS Growth
- DSP N/A
- ITOS N/A
- EPS
- DSP 0.13
- ITOS N/A
- Revenue
- DSP $306,484,000.00
- ITOS $35,000,000.00
- Revenue This Year
- DSP $18.36
- ITOS N/A
- Revenue Next Year
- DSP $15.95
- ITOS N/A
- P/E Ratio
- DSP $99.73
- ITOS N/A
- Revenue Growth
- DSP 30.64
- ITOS 177.89
- 52 Week Low
- DSP $8.70
- ITOS $4.80
- 52 Week High
- DSP $26.33
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- DSP 55.14
- ITOS 66.97
- Support Level
- DSP $12.79
- ITOS $10.05
- Resistance Level
- DSP $13.85
- ITOS $10.21
- Average True Range (ATR)
- DSP 0.52
- ITOS 0.13
- MACD
- DSP 0.13
- ITOS -0.06
- Stochastic Oscillator
- DSP 86.80
- ITOS 81.48
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.